Vaxcyte, Inc. (PCVX) NASDAQ
47.70
+0.31(+0.65%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
47.70
+0.31(+0.65%)
Currency In USD
| Previous Close | 47.39 |
| Open | 47.35 |
| Day High | 48.37 |
| Day Low | 47.11 |
| 52-Week High | 65 |
| 52-Week Low | 29.08 |
| Volume | 678,571 |
| Average Volume | 1.69M |
| Market Cap | 6.89B |
| PE | -6.92 |
| EPS | -6.89 |
| Moving Average 50 Days | 56.62 |
| Moving Average 200 Days | 47.39 |
| Change | 0.31 |
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
GlobeNewswire Inc.
Feb 11, 2026 9:05 PM GMT
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech